Amgen Inc (AMGN)
Amgen Inc (AMGN) carries a ŷRobot AI score of 65 out of 100. The model's fair value estimate is $525.02, 12.7% above the last close of $465.67. The chart signal reads Sell.
| Metric | AMGN |
|---|---|
| AI score | 65 / 100 |
| Chart signal | Sell |
| Fair value estimate | $525.02 |
| Upside to fair value | 12.7% |
| Previous close | $465.67 |
| P/E | 28.65 |
| Price / sales | 6.79 |
| Market cap | $252.64B |
| EPS | 16.10 |
| Revenue growth | 11.7% |
| 1-year price change | 4.5% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about AMGN
Is AMGN overvalued or undervalued right now?
As of Nov 5, 2026, ŷRobot's fair-value model estimates Amgen Inc (AMGN) at $525.02 against a last close of $465.67, implying 12.7% upside to the model's estimate.
Is AMGN's chart signal bullish or bearish?
The chart-signal model classifies AMGN as Neutral as of Nov 13, 2026, with a signal score of -0.11 on a -1 to 1 scale.
What is AMGN's ŷRobot AI score?
AMGN scores 65 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is AMGN stock expensive on P/E and P/S?
AMGN trades at 28.6 times earnings and 6.8 times sales as of Nov 13, 2026.
What does AMGN's seasonal forecast show?
ŷRobot's seasonal forecast curve for AMGN reads -1.3% at 30 days, -0.5% at 90 days, and +4.5% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is AMGN growing?
Amgen Inc's revenue growth is +11.7% and free-cash-flow growth is +8.0% on the latest reported figures.
AMGN chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.